[ad_1]
- Revenue of the Group for the year ended December 31, 2021 was approximately US$511.1 million, representing an increase of 30.8% as compared with approximately US$390.8 million for the year ended December 31, 2020, among which, the external revenue for non-cell therapy business was approximately US$424.7 million, representing an increase of 34.8% as compared with approximately US$315.1 million for the year ended December 31, 2020, and the external revenue for cell therapy business was approximately US$86.4 million, representing an increase of 14.1% as compared with approximately US$75.7 million for the year ended December 31, 2020.
- The adjusted net profit of non-cell therapy business before eliminations was approximately US$50.2 million, representing an increase of 18.1% as compared with approximately US$42.5 million for the year ended December 31, 2020, and the adjusted net loss of cell therapy business before eliminations was approximately US$354.6 million, whilst the adjusted net loss of cell therapy business was approximately US$213.3 million for the year ended December 31, 2020.
- Gross profit of the Group for the year ended December 31, 2021 was approximately US$303.5 million, representing an increase of 18.6% as compared with approximately US$255.9 million recorded for the year ended December 31, 2020, among which, the gross profit of non-cell therapy business before eliminations was approximately US$223.4 million, representing an increase of 17.7% as compared with approximately US$189.8 million for the year ended December 31, 2020, and the gross profit of cell therapy business before eliminations was approximately US$89.8 million, representing an increase of 18.6% as compared with approximately US$75.7 million for the year ended December 31, 2020.
- During the Reporting Period, the Group invested significantly into research and development activities as well as talent recruitment, both of which are key drivers for a sustainable business growth in the long…
[ad_2]
